OrbiMed Advisors | Activity | F4

OrbiMed Advisors Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Altis Labs closed a $25M Series A co-led by OrbiMed and Qiming Venture Partners USA. OrbiMed Partner Tal Zaks will support the company. Altis develops AI endpoints for oncology clinical trials.

Altis Labs

Altis Labs OrbiMed Advisors

orbimed.comSEP 17, 2026

SEP 17, 2026

News

OrbiMed was named to TIME's America's Top Venture Capital Firms of 2026 ranking, published August 18, 2026.

OrbiMed Advisors

OrbiMed AdvisorsOrbiMed Advisors

orbimed.comAUG 18, 2026

AUG 18, 2026

Exit

BlossomHill Therapeutics, an OrbiMed portfolio company, priced its upsized $150M IPO on Nasdaq (ticker: BLSM) on August 6, 2026.

BlossomHill Therapeutics

BlossomHill Therapeutics OrbiMed Advisors

orbimed.comAUG 6, 2026

AUG 6, 2026

New Fund

OrbiMed Advisors Fund II filed SEC Form D on July 10, 2026, indicating a new fund raise.

OrbiMed Advisors

OrbiMed AdvisorsOrbiMed Advisors

valueaddvc.comJUL 10, 2026

JUL 10, 2026

Exit

Portfolio company RayThera agreed to be acquired by Biogen for up to $1B.

RayThera

RayTheraOrbiMed Advisors

globenewswire.comJUN 17, 2026

orbimed.com

JUN 17, 2026

Investment

Led Accro Bioscience's $50M Series C to advance its immune-mediated disease pipeline.

Accro Bioscience

Accro Bioscience OrbiMed Advisors

prnewswire.comMAY 18, 2026

MAY 18, 2026

Exit

Portfolio company PathAI entered a definitive merger agreement to be acquired by Roche for $750M upfront plus up to $300M in milestones.

PathAI

PathAI OrbiMed Advisors

globenewswire.comMAY 7, 2026

orbimed.com

MAY 7, 2026

Exit

Portfolio company Perfuse Therapeutics agreed to be acquired by Bayer for up to $2.45B.

Perfuse Therapeutics

Perfuse Therapeutics OrbiMed Advisors

bayer.comMAY 6, 2026

orbimed.com

MAY 6, 2026

4 investments· MAR 2026 – MAY 2026Show all

Investment

Led Windward Bio's upsized $165M crossover financing to advance long-acting immunology therapies.

Windward Bio

Windward Bio OrbiMed Advisors

globenewswire.comMAY 4, 2026

MAY 4, 2026

Investment

Led $50M financing for Nucleus RadioPharma to expand radiopharmaceutical manufacturing capacity.

Nucleus RadioPharma

Nucleus RadioPharma OrbiMed Advisors

tcbmag.comAPR 21, 2026

APR 21, 2026

Investment

Participated in Sidewinder Therapeutics' $137M Series B financing to advance next-generation bispecific ADCs for cancer.

Sidewinder Therapeutics

Sidewinder Therapeutics OrbiMed Advisors

sidewinderbio.comAPR 8, 2026

APR 8, 2026

Investment

Co-led $39.5M financing for Congruence Therapeutics to advance small molecule correctors into clinical trials.

Congruence Therapeutics

Congruence Therapeutics OrbiMed Advisors

prnewswire.comMAR 19, 2026

MAR 19, 2026

News

OrbiMed vaulted to the number one slot on Endpoints News' top 100 list of biotech venture investors in 2026.

OrbiMed Advisors

OrbiMed AdvisorsOrbiMed Advisors

orbimed.comFEB 26, 2026

FEB 26, 2026

Exit

Braveheart Bio, an OrbiMed portfolio company, announced pricing of its upsized initial public offering.

Braveheart Bio

Braveheart Bio OrbiMed Advisors

orbimed.comJAN 1, 2026

JAN 1, 2026

Page 1 of 2